Skip to main content

Black Listed News
Trending Articles:
Trending Articles:

OxyContin maker Purdue Pharma pleads guilty in criminal case

Published: November 24, 2020 | Print Friendly and PDF
  Gab
 

Source: ap news

Purdue Pharma pleaded guilty Tuesday to three criminal charges, formally taking responsibility for its part in an opioid epidemic that has contributed to hundreds of thousands of deaths but also angering critics who want to see individuals held accountable, in addition to the company.

In a virtual hearing with a federal judge in Newark, New Jersey, the OxyContin maker admitted impeding the U.S. Drug Enforcement Administration’s efforts to combat the addiction crisis.

Purdue acknowledged that it had not maintained an effective program to prevent prescription drugs from being diverted to the black market, even though it had told the DEA it did have such a program, and that it provided misleading information to the agency as a way to boost company manufacturing quotas.

It also admitted paying doctors through a speakers program to induce them to write more prescriptions for its painkillers.

And it admitted paying an electronic medical records company to send doctors information on patients that encouraged them to prescribe opioids.

The guilty pleas were entered by Purdue board chairperson Steve Miller on behalf of the company. They were part of a criminal and civil settlement announced last month between the Stamford, Connecticut-based company and the Justice Department.

Read More...

Share This Article...


Image result for patreon


PLEASE DISABLE AD BLOCKER TO VIEW DISQUS COMMENTS

Ad Blocking software disables some of the functionality of our website, including our comments section for some browsers.


Gab Social Gettr Twitter T Facebook RSS

Image result for patreon

Support Blacklisted News
and Kill The ADS!!!

Become our Patreon and get access to the ad free version of the website and other insider exclusives for $1.00

Login with patreon to gain access to perks!




BlackListed News 2006-2022
Privacy Policy
Terms of Service